A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer

European Journal of Cancer

Volumn 39, Issue 10, 2003, Pages 1377-1383

  Smith, D ^a   Gallagher, N ^b  

^a CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Efficacy; Gemcitabine; Pancreatic cancer; Safety; ZD9331

Indexed keywords

FOLIC ACID ANTAGONIST; GEMCITABINE; PLEVITREXED;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; BLOOD TOXICITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FATIGUE; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MELENA; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PURPURA; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THRUSH; TREATMENT OUTCOME;

EID: 0038121964     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00271-5     Document Type: Article

References (18)

1. Ferlay J., Bray F., Pisani P., Parkin D.M. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No. 5. 2001;IARC Press, Lyon.
2. Riess H., Htun P., Loffel J., Huhn D. Chemotherapy for patients with adenocarcinoma of the pancreas. Recent Results Cancer Res. 142:1996;415-424.
3. Ahlgren J.D. Chemotherapy for pancreatic carcinoma. Cancer. 78(Suppl. 3):1996;654-663.
4. Crown J., Casper E.S., Botet J., Murray P., Kelsen D.P. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J. Clin. Oncol. 9:1991;1682-1686.
5. DeCaprio J.A., Mayer R.J., Gonin R., Arbuck S.G. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas. results of a phase II trial J. Clin. Oncol. 9:1991;2128-2133.
6. Bukowski R.M., Balcerzak S.P., O'Bryan R.M., Bonnet J.D., Chen T.T. Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest Oncology Group Study. Cancer. 52:1983;1577-1582.
7. Oster M.W., Gray R., Panasci L., Perry M.C. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer. 57:1986;29-33.
8. Kelsen D., Hudis C., Niedzwiecki D.et al. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 68:1991;965-969.
9. Burris III H., Moore M.J., Andersen J.et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer. a randomized trial J. Clin. Oncol. 15:1997;2403-2413.
10. Jackman A.L., Kimbell R., Aherne G.W.et al. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331. a water-soluble, nonpolyglutamatable quinazoline-based inhibitor of thymidylate synthase Clin. Cancer Res. 3:1997;911-921.
11. Boyle F.T., Stephens T.C., Averbuch S.D., Jackman A.L. ZD9331: Preclinical and clinical studies. Jackman A.L. Cancer Drug Discovery and Development: Antifolate Drugs in Cancer Therapy. 1998;243-260 Humana Press, Totowa.
12. Diab S.G., Rha S.Y., Britten C.et al. Evaluation of the factors influencing the clearance of the novel thymidylate synthase inhibitor ZD9331. Eur. J. Cancer. 35(Suppl. 4):1999;S285. (abstr 1130).
13. Goh B.C., Ratain M.J., Bertucci D.et al. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J. Clin. Oncol. 19:2001;1476-1484.
14. Plummer R, Rees C, Hughes A, et al. A phase I trial of ZD9331, a water-soluble, non-polyglutamatable, thymidylate synthase inhibitor, given on days 1 and 8 of a 3-weekly cycle in advanced solid malignancies. Clin Cancer Res 2003, 9, 1313-1322.
15. Trigo J., Rees C., Beale P.et al. Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase inhibitor given as a 5-day continuous infusion every 3 weeks. Eur. J. Cancer. 35(Suppl. 4):1999;S286. (abstr 1135).
16. Rees C, Beale P, Trigo J, et al. Phase I trial of ZD9331, a non-polyglutamable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies. Clin Cancer Res (in press).
17. Therasse P., Arbuck S.G., Eisenhauer E.A.et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Institute of Cancer. J. Natl. Cancer Inst. 92:2000;205-216.
18. Gehan E.A. The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapy agent. J. Chron. Dis. 13:1961;346-353.